PHILADELPHIA, June 07, 2024–(BUSINESS WIRE)–GSK plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved AREXVY (Respiratory Syncytial Virus (RSV) Vaccine, Adjuvanted) for the prevention of RSV lower respiratory tract disease (LRTD) in adults 50 through 59 years of age who are at increased risk. In the US, the vaccine is currently approved for use in adults aged 60 and older and recommended by CDC/ACIP using shared clinical decision-making.
OXFORD, United Kingdom, June 06, 2024 (GLOBE NEWSWIRE) — Barinthus Biotherapeutics plc (NASDAQ: BRNS), a biopharmaceutical company developing novel T cell immunotherapeutic candidates, today announced the presentation of updated data from two clinical trials in people with chronic hepatitis B (CHB) at the European Association for the Study of the Liver (EASL) Congress 2024. The presentations include updated interim data from the Phase 2b clinical trial (HBV003), as well as new interim EOT data from the Phase 2a clinical trial (IM-PROVE II, AB-729-202) in partnership with Arbutus Biopharma (NASDAQ: ABUS), both in people with CHB receiving ongoing SoC NUC therapy.
REPROCELL USA is proud to announce that it has received funding from MSCRF for both proposals it has submitted for the MSCRF’s January 2024 grant cycle. These two grants will help us produce Master Cell Banks (MCB) for cell therapy and enhance our capacity to produce therapeutic cell products.
BELTSVILLE, Md., June 5, 2024 /PRNewswire/ — REPROCELL is a leader in producing clinically relevant human induced pluripotent stem cells (hiPSCs). These hiPSCs are generated from healthy donors that have been screened for eligibility using the questionnaire established by the US Food & Drug Administration (FDA). Further viral testing is performed to satisfy the requirements of FDA, European Medicines Agency (EMA) and Pharmaceutical and Medical Devices Agency (PMDA) of Japan. The first grant titled: “Generation of human iPSC and MSC MCBs and derivative products in an enclosed GMP system” will help REPROCELL offer two GMP grade cell lines in the next 8 to 12 months for commercialization. These products will be tested for quality and ready for off-the-shelf distribution and further differentiation internally, by other companies in Maryland and the rest of the world. This grant is funded by MSCRF under their commercialization grant that provides funding for commercializing the products.
ROCKVILLE, Md., June 5, 2024 /PRNewswire/ — I-Mab (NASDAQ: IMAB) (the “Company”), a U.S.-based, global biotech company, exclusively focused on the development and potential commercialization of highly differentiated immunotherapies for the treatment of cancer, today announced that it has entered into a clinical trial collaboration and supply agreement with Bristol Myers Squibb (NYSE: BMY). The collaboration will evaluate the combination of givastomig, an investigational Claudin 18.2 x 4-1BB bispecific antibody jointly developed by I-Mab and ABL Bio (KOSDAQ: 298380), with Bristol Myers Squibb’s immune checkpoint inhibitor, nivolumab, and chemotherapy (FOLFOX or CAPOX), as a potential first-line treatment for patients with advanced Claudin 18.2-positive gastric and esophageal cancers.
The firm deepens its 130-year presence in Baltimore and commitment to driving inclusive economic growth; advances $20 million five-year philanthropic commitment to BaltimoreJune 4, 2024 (Baltimore) – Today, JPMorgan Chase announced an $8.45 million philanthropic commitment to nonprofit organizations and programs across the city of Baltimore to support economic and community development. Specifically, the firm’s funding will address residential vacancies to stabilize housing supply and promote access to affordable homeownership; support commercial corridor revitalization; and promote small business growth. This announcement is the latest round of funding as part of the firm’s $20 million five-year commitment to benefit underserved communities across the city.
The philanthropic investments include:
Montgomery County, Maryland, is a top destination for the life sciences industry. Pete Briskman, JLL’s Executive Managing Director and Chair of BioHealth Innovation Inc.’s (BHI) Board of Directors, highlights several reasons why.
“Montgomery County is poised well in comparison to other regions,” Briskman said, pointing to its proximity to NIH and FDA and the strong talent pipeline from local universities.
Briskman also emphasized creative real estate solutions and the region’s strengths in cell and immunotherapy research. “Health care isn’t going away,” he noted, reflecting optimism about the sector’s growth.
Venlo, the Netherlands, and Salt Lake City, Utah, May 30, 2024 (GLOBE NEWSWIRE) — QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) and Myriad Genetics (NASDAQ: MYGN) today announced they will develop a globally distributable kit-based test for analyzing Homologous Recombination Deficiency (HRD) status. This next-generation sequencing (NGS) test aims to support research into personalized medicine in multiple solid tumor types, including ovarian cancer and is expected to enhance decentralized testing capacities once a regulated product is developed with pharmaceutical partners. The project builds on the recently announced master collaboration agreement between the two companies.
Washington, D.C., June 03, 2024 (GLOBE NEWSWIRE) — Children’s National Hospital is pleased to welcome Alda Mizaku in a newly established role of vice president and chief data and artificial intelligence officer (CDAIO). In this role, Mizaku will lead the execution of enterprise data, analytics and artificial intelligence (AI) strategy at Children’s National.
Mizaku has a track record of leading initiatives with measurable organizational value, from reducing unnecessary length of stay to enhancing operational efficiency and patient outcomes. Prior to joining Children’s National, Mizaku spent 11 years working for Mercy Health System in St. Louis, where she served in various roles, including executive director of Data Engineering and Analytics, and vice president of Analytics Product Management.
AstraZeneca intends to build a $1.5 billion manufacturing facility in Singapore for antibody drug conjugates (ADCs), enhancing global supply of its ADC portfolio. ADCs are next-generation treatments that deliver highly potent cancer-killing agents directly to cancer cells through a targeted antibody.
The planned greenfield facility, supported by the Singapore Economic Development Board (EDB), will be AstraZeneca’s first end-to-end ADC production site, fully incorporating all steps of the manufacturing process at a commercial scale. Manufacturing of ADCs is a multi-step process that comprises antibody production, synthesis of chemotherapy drug and linker, conjugation of drug-linker to the antibody, and filling of the completed ADC substance.
Did you know? Each year, the federal government dedicates around $3.6 billion towards SBIR and STTR programs, resulting in awards to over 5,000 innovative projects!
The next deadline for NIH SBIR/STTR proposals is September 5th. As an innovation intermediary, BioHealth Innovation (BHI) is here to help you secure federal funding.
If you’re seeking assistance, don’t hesitate to reach out to Jon Nelson at JNelson@BioHealthInnovation.org. Let’s innovate together!
